Arcturus Therapeutics (ARCT) Scheduled to Post Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Arcturus Therapeutics to post earnings of ($0.70) per share for the quarter.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The firm had revenue of $49.86 million during the quarter, compared to analysts' expectations of $21.00 million. During the same quarter in the prior year, the company earned ($1.98) EPS. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arcturus Therapeutics Stock Performance

ARCT stock traded up $0.27 during trading on Friday, reaching $18.00. 317,915 shares of the company traded hands, compared to its average volume of 467,195. The business has a 50 day simple moving average of $20.94 and a 200 day simple moving average of $24.64. Arcturus Therapeutics has a 12 month low of $17.50 and a 12 month high of $45.00. The company has a market capitalization of $484.74 million, a price-to-earnings ratio of -7.06 and a beta of 2.61.

Wall Street Analyst Weigh In

ARCT has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a report on Monday, August 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Finally, Leerink Partners initiated coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an "outperform" rating and a $70.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $71.40.

Insider Activity

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 15.30% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.